Neurocrine Biosciences, Inc.
NBIX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,355 | $1,887 | $1,489 | $1,134 |
| % Growth | 24.8% | 26.8% | 31.3% | – |
| Cost of Goods Sold | $34 | $40 | $23 | $14 |
| Gross Profit | $2,321 | $1,847 | $1,466 | $1,119 |
| % Margin | 98.6% | 97.9% | 98.4% | 98.7% |
| R&D Expenses | $731 | $565 | $464 | $328 |
| G&A Expenses | $816 | $0 | $0 | $0 |
| SG&A Expenses | $1,007 | $888 | $753 | $583 |
| Sales & Mktg Exp. | $191 | $0 | $0 | $0 |
| Other Operating Expenses | $13 | $144 | $0 | $105 |
| Operating Expenses | $1,751 | $1,597 | $1,217 | $1,017 |
| Operating Income | $571 | $251 | $249 | $103 |
| % Margin | 24.2% | 13.3% | 16.7% | 9% |
| Other Income/Exp. Net | -$85 | $81 | -$35 | -$1 |
| Pre-Tax Income | $486 | $332 | $214 | $101 |
| Tax Expense | $145 | $82 | $59 | $12 |
| Net Income | $341 | $250 | $155 | $90 |
| % Margin | 14.5% | 13.2% | 10.4% | 7.9% |
| EPS | 3.4 | 2.56 | 1.61 | 0.95 |
| % Growth | 32.8% | 59% | 69.5% | – |
| EPS Diluted | 3.29 | 2.47 | 1.56 | 0.92 |
| Weighted Avg Shares Out | 100 | 98 | 96 | 95 |
| Weighted Avg Shares Out Dil | 104 | 101 | 99 | 98 |
| Supplemental Information | – | – | – | – |
| Interest Income | $91 | $0 | $11 | $0 |
| Interest Expense | $127 | $5 | $7 | $26 |
| Depreciation & Amortization | $27 | $21 | $16 | $11 |
| EBITDA | $640 | $416 | $265 | $138 |
| % Margin | 27.2% | 22% | 17.8% | 12.2% |